Oncology
Refine Search
Pharmaceutical
Global drugmakers and their Russian partners are losing their positions in the Russian market for anti-cancer drugs due to expiration of patent protection for a number of their drugs and their replacement by Russian-made generics, reports The Pharma Letter’s local correspondent. 1 June 2022
Pharmaceutical
“We need to make sure that cancer care gets back on top of the priority list for societies. Cancer is a disease that every second person will face, and many people still die of. It deserves our full attention. It needs to be back on the political agenda so that, collaboratively, we can change that trajectory.” 31 May 2022
Biotechnology
New pivotal data is to be presented on Roche’s CD20xCD3 T-cell engaging bispecific antibody, glofitamab at this week’s 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2022 Congress. 30 May 2022
Pharmaceutical
Swiss drug discovery company Cureteq has in-licensed its first compound, from Germany’s Merck KGaA. 30 May 2022
Biotechnology
At the 2022 annual meeting of the American Society of Clinical Oncology (ASCO 22), Shanghai-based cancer company I-Mab is presenting new Phase I data for uliledlimab. 30 May 2022
Biosimilars
US drugmaker Amneal has announced that the US Food and Drug Administration (FDA) has approved the company’s Biologics License Application (BLA) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta. 30 May 2022
Biotechnology
The US Food and Drug Administration has granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy, said Swiss pharma giant Novartis. 28 May 2022
Pharmaceutical
Oncology trial starts reached historically high levels in 2021, up 56% from 2016 and mostly focused on rare cancer indications. 27 May 2022
Biotechnology
US biotech major Amgen has promised new data from across its oncology innovative medicines and biosimilars portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting next week. 27 May 2022
Biotechnology
Japanese drugmaker Chugai Pharmaceutical announced that it launched anti VEGF/anti Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120 g/mL (faricimab [genetical recombination]) for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema (DME). 26 May 2022
Biotechnology
Roche has won approval from the European Commission (EC) for the use of Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adults with untreated diffuse large B-cell lymphoma (DLBCL). 26 May 2022
Biotechnology
Germany’s CureVac and myNEO, a Belgium-based immunotherapy company, have entered into a research and option agreement. 26 May 2022
Pharmaceutical
French privately-held drugmaker Servier has announced that the US Food and Drug Administration (FDA) approved Tibsovo (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. 26 May 2022
Biotechnology
An exclusive licensing agreement has been agreed by SunRock Biopharma, a Spanish company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and UK-based oncology-focused drug development firm, Ellipses Pharma. 25 May 2022
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Determination recommending Libtayo (cemiplimab). 25 May 2022
Pharmaceutical
The world’s leading cancer conference kicks off in Chicago on Friday June 3, and for many industry participants, it will be the first time they have attended a medical meeting in person since the pandemic started over two years ago. 25 May 2022
Biotechnology
Merck & Co’s blockbuster drug Keytruda (pembrolizumab) has been approved by the European Commission alongside chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer (TNBC) at high risk of recurrence. 25 May 2022
Biotechnology
Research from industry analyst GlobalData highlights the growing market opportunity for Pfizer in lung cancer. 25 May 2022
Pharmaceutical
Positive results for nirogacestat would appear to validate Pfizer’s strategy of spinning out assets that fall outside of its strategic focus. 25 May 2022
Biotechnology
The local subsidiary of Swiss pharma giant Roche has launched its Phesgo, the first-ever fixed-dose formulation in cancer treatment to combine two monoclonal antibodies, in India. 24 May 2022
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze